You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


CHMP recommends Nucala for three new indications

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended approval for GlaxoSmithKline’s Nucala (mepolizumab) in three additional eosinophil-driven diseases.